| Literature DB >> 26160846 |
Jue-feng Wan1, Ji Zhu1, Gui-chao Li1, Wen-jie Sun1, Zhen Zhang1.
Abstract
Patients were excluded if they were older than 75 years of age in most clinical trials. Thus, the optimal treatment strategies in elderly patients with locally advanced rectal cancer (LARC) are still controversial. We designed our study to specifically evaluate the cancer specific survival of four subgroups of patients according to four different treatment modalities: surgery only, radiation (RT) only, neoadjuvant RT and adjuvant RT by analyzing the Surveillance, Epidemiology, and End Results (SEER)-registered database. The results showed that the 5-year cancer specific survival (CSS) was 52.1% in surgery only, 27.7% in RT only, 70.4% in neoadjuvant RT and 60.4% in adjuvant RT, which had significant difference in univariate log-rank test (P < 0.001) and multivariate Cox regression (P < 0.001). Thus, the neoadjuvant RT and surgery may be the optimal treatment pattern in elderly patients, especially for patients who are medically fit for the operation.Entities:
Keywords: SEER; elderly; optimal; rectal cancer
Mesh:
Year: 2015 PMID: 26160846 PMCID: PMC4745806 DOI: 10.18632/oncotarget.4599
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Patient characteristics
| Variable | Total | Surgery only | RT only | Neoadjuvant RT | Adjuvant RT | P value |
|---|---|---|---|---|---|---|
| n=4,121 | n=1,460 | n=577 | n=1,498 | n=586 | ||
| Sex | <0.001 | |||||
| Male | 2077 | 45.8% | 48.2% | 55.3% | 51.4% | |
| Female | 2044 | 54.2% | 51.8% | 44.7% | 48.6% | |
| Race | 0.359 | |||||
| White | 3504 | 85.8% | 82.3% | 85.1% | 85.5% | |
| Black | 265 | 5.6% | 8.5% | 6.6% | 6% | |
| Other | 352 | 8.6% | 9.2% | 8.3% | 8.5% | |
| Pathological grading | <0.001 | |||||
| Grade I | 412 | 9% | 10.9% | 9.7% | 12.3% | |
| Grade II | 2703 | 67.9% | 62.9% | 66.9% | 59% | |
| Grade III | 380 | 10% | 8% | 8.9% | 9.2% | |
| Grade IV | 65 | 1% | 2.9% | 1.2% | 2.6% | |
| Unknown | 561 | 12.1% | 15.3% | 13.2% | 16.9% | |
| Histological Type | <0.001 | |||||
| Adenocarcinoma | 3847 | 93.3% | 97.6% | 92.3% | 92% | |
| Mucinous/Signet ring cell | 274 | 6.7% | 2.4% | 7.7% | 8% |
Figure 1Patterns of care are illustrated for patients who were diagnosed with rectal cancer from 2004 to 2011 according to treatment modality
RT indicates radiotherapy.
Figure 2Survival curves in rectal patients according to four subgroups
The 5-year cancer specific survival was 52.1% in surgery only, 27.7% in RT only, 70.4% in neoadjuvant RT and 60.4% in adjuvant RT, which had significant difference in univariate log-rank test (P < 0.001) and multivariate Cox regression (P < 0.001).
Univariate and multivariate survival analyses of rectal cancer patients according to various clinicopathological variables
| Variable | n | 5-year CSS (%) | Univariate | Multivariate |
|---|---|---|---|---|
| P | P | |||
| Sex | 0.224 | 0.601 | ||
| Male | 2077 | 58.6 | ||
| Female | 2044 | 56.9 | ||
| Race | 0.288 | 0.259 | ||
| White | 3504 | 57.2 | ||
| Black | 265 | 57.6 | ||
| Other | 352 | 63.9 | ||
| Treatment pattern | <0.001 | <0.001 | ||
| Surgery only | 1460 | 52.1 | ||
| RT only | 577 | 27.7 | ||
| Neoadjuvant RT | 1498 | 70.4 | ||
| Adjuvant RT | 586 | 60.4 | ||
| Histological Type | 0.022 | 0.013 | ||
| Adenocarcinoma | 3847 | 58 | ||
| Mucinous /Signet ring cell | 274 | 53.2 |